Development and Validation of a Nonremission Risk Prediction Model in First-Episode Psychosis: An Analysis of 2 Longitudinal Studies.
View / Open Files
Authors
Leighton, Samuel P
Krishnadas, Rajeev
Upthegrove, Rachel
Marwaha, Steven
Steyerberg, Ewout W
Broome, Matthew R
Liddle, Peter F
Everard, Linda
Singh, Swaran P
Freemantle, Nicholas
Fowler, David
Jones, Peter B
Sharma, Vimal
Murray, Robin
Wykes, Til
Cavanagh, Jonathan
Lewis, Shon W
Birchwood, Max
Mallikarjun, Pavan K
Publication Date
2021-01-01Journal Title
Schizophrenia bulletin open
Volume
2
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Leighton, S. P., Krishnadas, R., Upthegrove, R., Marwaha, S., Steyerberg, E. W., Gkoutos, G. V., Broome, M. R., et al. (2021). Development and Validation of a Nonremission Risk Prediction Model in First-Episode Psychosis: An Analysis of 2 Longitudinal Studies.. Schizophrenia bulletin open, 2 (1) https://doi.org/10.1093/schizbullopen/sgab041
Abstract
Psychosis is a major mental illness with first onset in young adults. The prognosis is poor in around half of the people affected, and difficult to predict. The few tools available to predict prognosis have major weaknesses which limit their use in clinical practice. We aimed to develop and validate a risk prediction model of symptom nonremission in first-episode psychosis. Our development cohort consisted of 1027 patients with first-episode psychosis recruited between 2005 and 2010 from 14 early intervention services across the National Health Service in England. Our validation cohort consisted of 399 patients with first-episode psychosis recruited between 2006 and 2009 from a further 11 English early intervention services. The one-year nonremission rate was 52% and 54% in the development and validation cohorts, respectively. Multivariable logistic regression was used to develop a risk prediction model for nonremission, which was externally validated. The prediction model showed good discrimination C-statistic of 0.73 (0.71, 0.75) and adequate calibration with intercept alpha of 0.12 (0.02, 0.22) and slope beta of 0.98 (0.85, 1.11). Our model improved the net-benefit by 15% at a risk threshold of 50% compared to the strategy of treating all, equivalent to 15 more detected nonremitted first-episode psychosis individuals per 100 without incorrectly classifying remitted cases. Once prospectively validated, our first episode psychosis prediction model could help identify patients at increased risk of nonremission at initial clinical contact.
Keywords
Schizophrenia, Prognosis, Logistic regression, early intervention, Psychotic Disorders, Precision Medicine
Sponsorship
UK Department of Health (RDD/ARF2)
National Institute of Health Research (RP-PG-0109-10074)
UK Medical Research Council and Department of Health (G0300610)
Chief Scientist Office, Scotland (CAF/19/04)
Chief Scientist Office (CAF/19/04)
Wellcome Trust (104025/Z/14/Z)
Identifiers
PMC8458108, 34568827
External DOI: https://doi.org/10.1093/schizbullopen/sgab041
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330023
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk